Biotech Startups

Origin generates spatial molecular maps from patient tumor samples to enable cancer biology research in native tissue context. The platform combines spatial transcriptomics, imaging, and functional perturbation assays on fresh and archived tumors, paired with AI models for drug response prediction and target discovery.

2 investors

Origin Sciences applies a hologenomic approach integrating host genetics, epigenetics, and microbiome analysis into a single diagnostic framework for deeper health assessment. The company works with leading institutions and technology providers to develop and scale advanced diagnostic assays for clinical and research applications.

2 investors

Orikine Bio develops engineered cytokines called Foldikines™ to reprogram immune responses for treating autoimmune and inflammatory diseases. The platform uses bi-specific cytokines designed to target specific immune cells with precision while minimizing off-target toxicities.

2 investors

OrisDX develops a non-invasive salivary-rinse DNA test called Oro Lesion to detect early markers of oral cavity squamous cell carcinoma in adults with indeterminate oral lesions. It pairs the test with Oris Bridge, a digital health patient navigator that handles clinical referrals, patient education, and medical claim automation and review.

2 investors

Clinical-stage biotech developing therapies for inadequately-controlled gastrointestinal disorders.

2 investors

OrthoPreserve develops a minimally invasive meniscus implant for orthopedic care, designed to address unmet clinical needs in knee surgery. The company is co-founded by orthopedic clinicians and engineers with expertise across R&D, manufacturing, regulatory compliance, and surgical practice.

2 investors

Oruka is a biopharmaceutical company developing monoclonal antibody therapies aimed at treating plaque psoriasis, psoriatic arthritis, and other dermatologic and inflammatory conditions with fewer annual doses. Its pipeline includes clinical-stage candidates ORKA-001 and ORKA-002 for moderate-to-severe plaque psoriasis.

2 investors

Osseus builds a permissioned research brain that connects tools and data across R&D teams to surface past experiments, expert knowledge, and next actions. The platform serves technical and research teams in biotech, manufacturing, and similar knowledge-intensive industries by maintaining continuous memory of how work evolved and preventing repeated efforts.

2 investors

Ottimo is a biotech company developing oncology and immuno-oncology therapeutics, including antibody-based cancer treatments. Its leadership and preclinical work focus on discovery through clinical development of cancer therapies.

2 investors

Outlander Materials develops microbial nanocellulose through controlled fermentation, engineered for industrial-scale production and cost-efficient sustainable material applications. The company serves industries seeking high-performance bio-based alternatives to synthetic materials without compromising on performance or cost.

2 investors

Outpost operates a "lab-in-the-loop" platform combining high-throughput experiments with machine learning to model the human microbiome and predict how drugs, food ingredients, and formulations interact with microbial ecosystems. It serves drug and ingredient R&D teams with metabolism, toxicity, efficacy, and safety screening to de-risk candidates in development.

2 investors

Outrun Therapeutics is a preclinical biotech developing small molecule E3 ligase inhibitors to stabilise tumour suppressor proteins for treating cancer and other diseases. Its lead programme targets an E3 ligase in hard-to-treat solid tumours.

2 investors

Ovid Therapeutics develops medicines for children and adults with epilepsies and brain conditions, focusing on anti-seizure and neurological treatments. The company is led by a team with decades of combined experience in biotech and pharmaceutical development, having supported the launch of more than 25 new medicines.

2 investors

Ovipost builds automated insect farms that convert cheap agricultural byproducts into protein-rich insect biomass. The company targets the animal feed industry, aiming to provide an alternative to fishmeal and other expensive feed proteins.

2 investors

Owlo develops patented optical imaging technology that enables non-invasive, real-time 3D imaging deep within biological tissue. The company targets applications in IVF, drug discovery, and ophthalmology.

2 investors

Owlstone Medical develops a breath-based diagnostic platform for non-invasive disease detection across respiratory conditions, cancers, and digestive health. The company serves academic, clinical, and pharmaceutical research partners seeking to develop breath biomarker applications for precision medicine and early diagnosis.

2 investors

Oxford Biomedica is a biopharmaceutical contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, lentiviral vector technologies, and bioprocessing solutions. The company provides manufacturing, development, and technical services to clients developing advanced therapies.

2 investors

Oxford Brain Diagnostics provides CDM Insights, a clinical software platform that analyzes MRI scans to detect and monitor microstructural changes in the brain for early diagnosis of neurodegenerative conditions. The platform integrates with standard hospital MRI systems and delivers quantitative brain assessment reports to clinicians within 12 hours.

2 investors

Oxford Medical Products develops medical devices, drawing on a team of biotech entrepreneurs, material scientists, polymer chemists and medical device engineers.

2 investors

A healthcare company that develops and supplies medicines, including new and more affordable therapies, aiming for reliable supply of needed treatments. Its offerings reference products such as a once-weekly combined hormonal contraceptive patch.

2 investors

Play Health builds a clinical decision-support platform for healthcare providers to deliver personalized menopause and women's health care. The platform serves primary care physicians and other providers treating women navigating perimenopause and menopause.

2 investors

Pacific Biosciences develops long-read DNA and RNA sequencing platforms and kits for genomics research, including whole genome, targeted, epigenetic, and RNA sequencing applications. The company serves research institutions, clinical laboratories, and diagnostic organizations in genomics and life sciences.

2 investors

Pacific Hybreed develops commercial shellfish breeding programs and genetics tools to improve yield and disease resilience for U.S. West Coast aquaculture. The company applies shellfish genetics research to make farmed shellfish more resilient to climate change, ocean acidification, and disease.

2 investors

PAGE Therapeutics is an oncology drug development company developing compounds that disrupt cell-cell adhesion to dissolve circulating tumor cell (CTC) clusters and block cancer metastasis. Its lead work includes preclinical models and a proof-of-concept clinical trial in breast cancer patients.

2 investors